Sanara MedTech (NASDAQ:SMTI – Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.18, FiscalAI reports. The company had revenue of $27.80 million for the quarter, compared to analyst estimates of $26.80 million. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%.
Sanara MedTech Stock Performance
Shares of SMTI stock traded down $0.38 during mid-day trading on Monday, reaching $18.02. The stock had a trading volume of 34,353 shares, compared to its average volume of 58,410. The firm has a market cap of $165.15 million, a PE ratio of -4.26 and a beta of 1.16. Sanara MedTech has a one year low of $16.05 and a one year high of $35.95. The firm’s 50 day simple moving average is $18.82 and its 200 day simple moving average is $21.74. The company has a quick ratio of 1.59, a current ratio of 1.80 and a debt-to-equity ratio of 7.75.
Analyst Ratings Changes
Several research firms have issued reports on SMTI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research note on Tuesday, April 21st. Lake Street Capital started coverage on Sanara MedTech in a research note on Wednesday, April 15th. They set a “buy” rating and a $32.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of Sanara MedTech in a research report on Monday, January 26th. Wall Street Zen lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating in a research note on Sunday, April 5th. Finally, Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sanara MedTech presently has an average rating of “Hold” and a consensus price target of $34.00.
Institutional Investors Weigh In On Sanara MedTech
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Sanara MedTech by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after purchasing an additional 6,049 shares during the last quarter. Royal Bank of Canada raised its position in shares of Sanara MedTech by 127.3% during the fourth quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after acquiring an additional 65,887 shares during the last quarter. Geode Capital Management LLC increased its position in Sanara MedTech by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock worth $1,846,000 after purchasing an additional 546 shares during the period. Marshall Wace LLP grew its position in shares of Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares during the period. Finally, State Street Corp boosted its stake in Sanara MedTech by 1.1% in the fourth quarter. State Street Corp now owns 62,289 shares of the company’s stock valued at $1,454,000 after acquiring an additional 690 shares during the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.
Sanara MedTech Company Profile
Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.
With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.
Featured Articles
- Five stocks we like better than Sanara MedTech
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
